Marc J. Gurwith
Geen lopende functies
Profiel
Marc J.
Gurwith worked as VP-Clinical Research & Associate Medical Director at SEQUUS Pharmaceuticals, Inc. from 1995 to 1997.
He then worked as Senior Director-Clinical Research at Wyeth-Ayerst Research.
In 1997, he became the Chief Medical Officer & VP-Drug Development at Genelabs Technologies, Inc. and held the position until 2001.
From 2001 to 2007, he worked as Chief Medical Officer & Senior VP-Medical Affairs at VaxGen, Inc. In 2010, he became the Chief Marketing Officer at Emergent Travel Health, Inc. and held the position until 2018.
Prior to his business career, he earned a doctorate degree from Harvard University, an undergraduate degree from Yale University, and a graduate degree from Temple University Beasley School of Law.
Eerdere bekende functies van Marc J. Gurwith
| Bedrijven | Functie | Einde |
|---|---|---|
Emergent Travel Health, Inc.
 Emergent Travel Health, Inc. Internet Software/ServicesTechnology Services Emergent Travel Health, Inc. develops vaccines against infectious diseases. The firm develops vaccines against typhoid, cholera, hepatitis, anthrax, and other infectious diseases. Its proprietary adenoviral-based technology platform enables the rapid development of oral vaccines that can target viral or bacterial protein antigen. The company was founded by Kenneth Kelley and Daniel R. Henderson in 2007 and is headquartered in San Diego, CA. | Verkoop & Marketing | 01-10-2018 |
VaxGen, Inc.
 VaxGen, Inc. BiotechnologyHealth Technology VaxGen, Inc. is a biopharmaceutical company, owns a state-of-the-art biopharmaceutical manufacturing facility that can be used to make cell culture or microbial biologic products. The company has ended all product development activities and sold or otherwise terminated its drug development programs. It is seeking to maximize the value of its remaining tangible and intangible assets through a transaction or series of transactions, including the sale of the manufacturing facility. The company was founded on November 01, 1995 and is headquartered in South San Francisco, CA. | Hoofd Techniek/Wetenschap/O&O | 30-11-2007 |
Genelabs Technologies, Inc.
 Genelabs Technologies, Inc. Pharmaceuticals: MajorHealth Technology Genelabs Technologies, Inc. discovery and development of pharmaceutical products to improve human health. The company was founded by Brian D. Frenzel and Frank C. Kung in 1983 and is headquartered in Redwood, CA. | Hoofd Techniek/Wetenschap/O&O | 01-10-2001 |
SEQUUS Pharmaceuticals, Inc.
 SEQUUS Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology SEQUUS Pharmaceuticals, Inc. is based in Menlo Park, CA. Part of Johnson & Johnson, SEQUUS Pharmaceuticals, Inc. is a company that markets lipid-based biopharmaceutical products mainly to treat cancer and infectious diseases. SEQUUS Pharmaceuticals was acquired by ALZA Corp., part of Johnson & Johnson from June 22, 2001 on March 16, 1999 for $658.03 million. | Hoofd Techniek/Wetenschap/O&O | 01-08-1997 |
| Wyeth-Ayerst Research | Hoofd Techniek/Wetenschap/O&O | - |
Opleiding van Marc J. Gurwith
| Harvard University | Doctorate Degree |
| Yale University | Undergraduate Degree |
| Temple University Beasley School of Law | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 6 |
|---|---|
VaxGen, Inc.
VaxGen, Inc. BiotechnologyHealth Technology VaxGen, Inc. is a biopharmaceutical company, owns a state-of-the-art biopharmaceutical manufacturing facility that can be used to make cell culture or microbial biologic products. The company has ended all product development activities and sold or otherwise terminated its drug development programs. It is seeking to maximize the value of its remaining tangible and intangible assets through a transaction or series of transactions, including the sale of the manufacturing facility. The company was founded on November 01, 1995 and is headquartered in South San Francisco, CA. | Health Technology |
Genelabs Technologies, Inc.
Genelabs Technologies, Inc. Pharmaceuticals: MajorHealth Technology Genelabs Technologies, Inc. discovery and development of pharmaceutical products to improve human health. The company was founded by Brian D. Frenzel and Frank C. Kung in 1983 and is headquartered in Redwood, CA. | Health Technology |
SEQUUS Pharmaceuticals, Inc.
SEQUUS Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology SEQUUS Pharmaceuticals, Inc. is based in Menlo Park, CA. Part of Johnson & Johnson, SEQUUS Pharmaceuticals, Inc. is a company that markets lipid-based biopharmaceutical products mainly to treat cancer and infectious diseases. SEQUUS Pharmaceuticals was acquired by ALZA Corp., part of Johnson & Johnson from June 22, 2001 on March 16, 1999 for $658.03 million. | Health Technology |
| Boehringer Mannheim Pharmaceuticals Corp. | |
| Wyeth-Ayerst Research | |
Emergent Travel Health, Inc.
Emergent Travel Health, Inc. Internet Software/ServicesTechnology Services Emergent Travel Health, Inc. develops vaccines against infectious diseases. The firm develops vaccines against typhoid, cholera, hepatitis, anthrax, and other infectious diseases. Its proprietary adenoviral-based technology platform enables the rapid development of oral vaccines that can target viral or bacterial protein antigen. The company was founded by Kenneth Kelley and Daniel R. Henderson in 2007 and is headquartered in San Diego, CA. | Technology Services |
